Analysts expect United Therapeutics Co. (NASDAQ:UTHR) to post $3.37 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for United Therapeutics’ earnings. The highest EPS estimate is $4.34 and the lowest is $2.80. United Therapeutics posted earnings per share of $6.27 during the same quarter last year, which would indicate a negative year-over-year growth rate of 46.3%. The company is scheduled to announce its next earnings results on Wednesday, October 24th.

According to Zacks, analysts expect that United Therapeutics will report full-year earnings of $13.71 per share for the current fiscal year, with EPS estimates ranging from $12.66 to $15.00. For the next financial year, analysts forecast that the firm will report earnings of $11.14 per share, with EPS estimates ranging from $8.08 to $13.59. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million for the quarter, compared to analysts’ expectations of $368.63 million. During the same quarter last year, the company earned $4.37 EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year.

UTHR has been the topic of several research analyst reports. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 13th. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 target price on the stock in a research note on Saturday, July 7th. Credit Suisse Group raised their target price on shares of United Therapeutics from $104.00 to $107.00 and gave the company a “neutral” rating in a research note on Tuesday, July 10th. Wedbush lifted their price objective on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. United Therapeutics has a consensus rating of “Hold” and a consensus target price of $138.86.

In other news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Insiders sold 8,100 shares of company stock valued at $977,508 over the last quarter. Corporate insiders own 8.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BancorpSouth Bank raised its position in shares of United Therapeutics by 11.4% in the second quarter. BancorpSouth Bank now owns 3,884 shares of the biotechnology company’s stock valued at $440,000 after purchasing an additional 397 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in United Therapeutics by 9.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,319 shares of the biotechnology company’s stock worth $602,000 after acquiring an additional 446 shares during the period. Retirement Systems of Alabama increased its position in United Therapeutics by 0.8% during the second quarter. Retirement Systems of Alabama now owns 56,385 shares of the biotechnology company’s stock worth $6,380,000 after acquiring an additional 462 shares during the period. Wedbush Securities Inc. increased its position in United Therapeutics by 13.5% during the second quarter. Wedbush Securities Inc. now owns 4,210 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 500 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in United Therapeutics by 5.6% during the first quarter. Thrivent Financial for Lutherans now owns 9,852 shares of the biotechnology company’s stock worth $1,107,000 after acquiring an additional 521 shares during the period. 95.85% of the stock is currently owned by institutional investors.

United Therapeutics stock opened at $124.52 on Tuesday. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 6.90, a P/E/G ratio of 27.85 and a beta of 1.24. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. United Therapeutics has a 52 week low of $100.57 and a 52 week high of $152.55.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More: What is a Tariff?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.